| Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis D Caridha, B Vesely, K van Bocxlaer, B Arana, CE Mowbray, S Rafati, ... International Journal for Parasitology: Drugs and Drug Resistance 11, 106-117, 2019 | 73 | 2019 |
| Leishmaniasis immunopathology—impact on design and use of vaccines, diagnostics and drugs PM Kaye, I Cruz, A Picado, K Van Bocxlaer, SL Croft Seminars in immunopathology 42, 247-264, 2020 | 71 | 2020 |
| Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis K Van Bocxlaer, D Caridha, C Black, B Vesely, S Leed, RJ Sciotti, ... International Journal for Parasitology: Drugs and Drug Resistance 11, 129-138, 2019 | 68 | 2019 |
| Drug permeation and barrier damage in Leishmania-infected mouse skin K Van Bocxlaer, V Yardley, S Murdan, SL Croft Journal of Antimicrobial Chemotherapy 71 (6), 1578-1585, 2016 | 60 | 2016 |
| Topical formulations of miltefosine for cutaneous leishmaniasis in a BALB/c mouse model K Van Bocxlaer, V Yardley, S Murdan, SL Croft Journal of Pharmacy and Pharmacology 68 (7), 862-872, 2016 | 53 | 2016 |
| Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome® and AmBisome® in murine cutaneous leishmaniasis GJ Wijnant, K Van Bocxlaer, V Yardley, A Harris, M Alavijeh, ... International Journal for Parasitology: Drugs and Drug Resistance 8 (2), 223-228, 2018 | 49 | 2018 |
| Activity of amphotericin B-loaded chitosan nanoparticles against experimental cutaneous leishmaniasis A Riezk, K Van Bocxlaer, V Yardley, S Murdan, SL Croft Molecules 25 (17), 4002, 2020 | 45 | 2020 |
| Characterization of a new Leishmania major strain for use in a controlled human infection model H Ashwin, J Sadlova, B Vojtkova, T Becvar, P Lypaczewski, E Schwartz, ... Nature Communications 12 (1), 215, 2021 | 42 | 2021 |
| Topical treatment for cutaneous leishmaniasis: dermato-pharmacokinetic lead optimization of benzoxaboroles K Van Bocxlaer, E Gaukel, D Hauser, SH Park, S Schock, V Yardley, ... Antimicrobial agents and chemotherapy 62 (5), 10.1128/aac. 02419-17, 2018 | 38 | 2018 |
| Relation between skin pharmacokinetics and efficacy in AmBisome treatment of murine cutaneous leishmaniasis GJ Wijnant, K Van Bocxlaer, V Yardley, A Harris, S Murdan, SL Croft Antimicrobial agents and chemotherapy 62 (3), 10.1128/aac. 02009-17, 2018 | 34 | 2018 |
| Efficacy of paromomycin-chloroquine combination therapy in experimental cutaneous leishmaniasis GJ Wijnant, K Van Bocxlaer, V Yardley, S Murdan, SL Croft Antimicrobial agents and chemotherapy 61 (8), 10.1128/aac. 00358-17, 2017 | 34 | 2017 |
| Local skin inflammation in cutaneous leishmaniasis as a source of variable pharmacokinetics and therapeutic efficacy of liposomal amphotericin B GJ Wijnant, K Van Bocxlaer, A Fortes Francisco, V Yardley, A Harris, ... Antimicrobial agents and chemotherapy 62 (10), 10.1128/aac. 00631-18, 2018 | 33 | 2018 |
| Pharmacokinetics and pharmacodynamics of the nitroimidazole DNDI-0690 in mouse models of cutaneous leishmaniasis GJ Wijnant, SL Croft, R de la Flor, M Alavijeh, V Yardley, S Braillard, ... Antimicrobial agents and chemotherapy 63 (9), 10.1128/aac. 00829-19, 2019 | 31 | 2019 |
| Tackling drug resistance and other causes of treatment failure in leishmaniasis GJ Wijnant, F Dumetz, L Dirkx, D Bulté, B Cuypers, K Van Bocxlaer, ... Frontiers in Tropical Diseases 3, 837460, 2022 | 23 | 2022 |
| Film-forming systems for the delivery of DNDI-0690 to treat cutaneous leishmaniasis K Van Bocxlaer, KN McArthur, A Harris, M Alavijeh, S Braillard, ... Pharmaceutics 13 (4), 516, 2021 | 15 | 2021 |
| A single dose of antibody-drug conjugate cures a stage 1 model of African trypanosomiasis P MacGregor, AL Gonzalez-Munoz, F Jobe, MC Taylor, S Rust, ... PLoS neglected tropical diseases 13 (5), e0007373, 2019 | 15 | 2019 |
| An efficient and novel technology for the extraction of parasite genomic DNA from whole blood or culture DJ Clark, CM Moore, M Flanagan, KV Bocxlaer, ET Piperaki, V Yardley, ... Biotechniques 68 (2), 79-84, 2019 | 9 | 2019 |
| AmBisome® treatment of murine cutaneous leishmaniasis: relation between skin pharmacokinetics and efficacy GJ Wijnant, K Van Bocxlaer, V Yardley, A Harris, S Murdan, SL Croft Antimicrob Agents Chemother 62, e02009-e02017, 2018 | 9 | 2018 |
| Pharmacokinetics and pharmacodynamics in the treatment of cutaneous leishmaniasis–challenges and opportunities K Van Bocxlaer, SL Croft RSC medicinal chemistry 12 (4), 472-482, 2021 | 8 | 2021 |
| Cutaneous Leishmaniasis-Skin Barrier Properties And Drug Delivery Strategies K Van Bocxlaer UCL (University College London), 2015 | 2 | 2015 |
